Eckert & Ziegler SE (ETR:EUZ)
60.40
-1.00 (-1.63%)
Feb 21, 2025, 5:05 PM CET
Eckert & Ziegler SE Revenue
Eckert & Ziegler SE had revenue of 70.11M EUR in the quarter ending September 30, 2024, with 6.39% growth. This brings the company's revenue in the last twelve months to 277.72M, up 15.56% year-over-year. In the year 2023, Eckert & Ziegler SE had annual revenue of 246.09M with 10.74% growth.
Revenue (ttm)
277.72M
Revenue Growth
+15.56%
P/S Ratio
4.54
Revenue / Employee
242.98K
Employees
1,075
Market Cap
1.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 246.09M | 23.86M | 10.74% |
Dec 31, 2022 | 222.23M | 41.79M | 23.16% |
Dec 31, 2021 | 180.44M | 4.30M | 2.44% |
Dec 31, 2020 | 176.14M | -2.35M | -1.32% |
Dec 31, 2019 | 178.49M | 9.78M | 5.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 22.67B |
Merck KGaA | 20.96B |
Bayer Aktiengesellschaft | 46.74B |
Fresenius SE & Co. KGaA | 22.81B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.24B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Eckert & Ziegler SE News
- 9 days ago - EQS-Adhoc: Eckert & Ziegler Affected by Cyber Attack - Wallstreet:Online
- 5 weeks ago - EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture - Wallstreet:Online
- 5 weeks ago - EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement - Wallstreet:Online
- 2 months ago - EQS-News: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW - Wallstreet:Online
- 2 months ago - EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments - Wallstreet:Online
- 2 months ago - EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply - Wallstreet:Online
- 3 months ago - EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand - Lutetium-177 Chloride (n.c.a) - Wallstreet:Online
- 3 months ago - Eckert & Ziegler Boosts Financial Year Forecast Again! - Wallstreet:Online